X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DS-234 is a fusion protein that is a highly selective and potent agonist of CD200R, an immune-regulatory receptor thought to be an important immunological checkpoint, with a pivotal role in maintenance of immune tolerance.
Lead Product(s): DS-234
Therapeutic Area: Dermatology Product Name: DS-234
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Arcutis Biotherapeutics
Deal Size: $400.0 million Upfront Cash: $16.0 million
Deal Type: Acquisition September 08, 2022
Details:
DS-234 offers a potential best-in-class profile, as well as a highly complementary treatment option to roflumilast cream which is in late-stage development for atopic dermatitis.
Lead Product(s): DS-234
Therapeutic Area: Dermatology Product Name: DS-234
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Arcutis Biotherapeutics
Deal Size: $30.0 million Upfront Cash: $16.0 million
Deal Type: Acquisition September 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
